What is Gameto?
Gameto is a pioneering biotechnology company focused on women's health, leveraging a proprietary cell engineering platform developed in collaboration with George Church's lab at Harvard Medical School. Founded by Dr. Dina Radenkovic, a medical doctor with entrepreneurial experience, and Martin Varsavsky, a notable figure in the fertility clinic network space, Gameto aims to advance novel therapeutic programs. The company's foundation in cutting-edge biological engineering positions it at the forefront of developing next-generation treatments for conditions affecting women's health.
How much funding has Gameto raised?
Gameto has raised a total of $158M across 5 funding rounds:
Series A
$20M
Other Financing Round
$17M
Series B
$33M
Series C
$44M
Private Equity
$44M
Series A (2022): $20M with participation from Future Ventures, Overwater Ventures, Robert Nelsen, BOLD Capital Partners, TA Ventures, Anne Wojcicki, Plum Alley, and Lux Capital
Other Financing Round (2022): $17M led by BOLD Capital Partners, Arcadia Investment Partners, Future Ventures, Insight Partners, and Plum Alley
Series B (2024): $33M supported by Insight Partners, Two Sigma Ventures, RA Capital Management, BOLD Capital Partners, and Future Ventures
Series C (2025): $44M featuring RA Capital Management, Two Sigma Ventures, Overwater Ventures, Arcadia Investment Group, Insight Partners, and BOLD Capital Partners
Private Equity (2025): $44M, investors not publicly disclosed
Key Investors in Gameto
Insight Partners
Insight Partners is a global venture capital and private equity firm that invests in high-growth software and technology companies, providing capital and operational support to help businesses scale.
Two Sigma Ventures
Two Sigma Ventures is an early-stage venture capital firm that invests in transformative companies leveraging information growth and computing power, focusing on technology that enhances human potential and breakthrough therapies.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, and diagnostics.
What's next for Gameto?
With the recent infusion of $44M in a major strategic investment, Gameto is poised for accelerated growth and the expansion of its research and development pipeline. This substantial backing, part of its overall $158M in capital, suggests a transition towards scaling operations and potentially moving key programs closer to clinical application. The company's strategic focus on leveraging advanced cell engineering for women's health issues indicates a significant opportunity to address unmet medical needs and capture a substantial market share. Future endeavors will likely involve further clinical validation, strategic partnerships, and the continued maturation of its technology platform.
See full Gameto company page
